A phase I/II safety and immunogenicity evaluation of a prime/boost vaccine using ALVAC-HIV (vCP 1452) with recombinant gp160 LAI/MN-2 in HIV-infected subjects treated with antiretroviral therapy for a minimum of 2 years
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2015
At a glance
- Drugs HIV gp160 vaccine (Primary) ; HIV vaccine vCP1452 (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Therapeutic Use
- 15 Oct 2005 New trial record.